Advance Tests, a leader in advanced diagnostics, is bringing a transformative solution to Alzheimer’s diagnosis in the UK with the exclusive launch of LucentAD Complete. Developed by Lucent Diagnostics, a brand of Quanterix Corporation, this innovative blood test combines multiple biomarkers, including p-Tau 217, to deliver highly accurate risk classification for amyloid pathology linked to Alzheimer’s Disease. Starting from 2 December 2024, the test will be accessible to UK patients and healthcare providers, offering a non-invasive and cost-effective alternative to traditional diagnostic methods.
What Makes LucentAD Complete Unique?
Early Booking Availability
Patients and healthcare providers in the UK can now book appointments for LucentAD Complete testing, with the first clinic opening on St Thomas Street, beside Guy’s Hospital near London Bridge station. Patient samples will be securely transported to Lucent laboratories in the USA, with results available within 15 working days.
High Accuracy
The test achieves an impressive 90% accuracy in detecting amyloid pathology, making it an effective tool for identifying early-stage Alzheimer’s Disease in individuals showing cognitive symptoms.
Affordable and Accessible
Priced at £695, LucentAD Complete provides a more affordable option compared to invasive PET imaging or lumbar punctures, which are significantly more expensive.
Non-Invasive Testing
Using only a simple blood sample, the test eliminates the need for cerebrospinal fluid (CSF) collection or complex imaging, ensuring a comfortable experience for patients.
Reduced Ambiguity in Results
By incorporating multiple biomarkers such as Aβ42/40, GFAP, and NfL into a sophisticated algorithmic model, the test minimises inconclusive outcomes. This approach enables nearly 90% of tested patients to receive a clear classification, either ruling in or ruling out Alzheimer’s Disease.
Setting New Standards in Alzheimer’s Diagnostics
LucentAD Complete is designed to exceed the performance criteria set by the Global CEO Initiative on Alzheimer’s Disease (CEOi) and the US Alzheimer’s Association (AA) for plasma-based diagnostic tools. Its innovative approach provides an advanced alternative to the current gold standards of CSF analysis or PET imaging, which are both invasive and costly.
“We are thrilled to introduce LucentAD Complete to the UK, providing healthcare professionals and patients with a dependable diagnostic tool that has the potential to transform Alzheimer’s care, stated Dr. Simon Worrell, Founder and Chief Medical Officer of Advance Tests. By partnering with Quanterix, we are breaking down barriers to early diagnosis and enabling timely treatment, potentially transforming patients’ lives.”
Expanding Access Across the UK
In addition to the first clinic in London, Advance Tests plans to establish more testing facilities across key cities, ensuring broader access to this revolutionary diagnostic tool. Appointments can be booked directly or through healthcare providers via www.advancetests.com, with services commencing from 2 December 2024.
Expert Perspectives
Dr. Karan Jutlla, Head of the Centre for Applied and Inclusive Health Research at the University of Wolverhampton, highlighted the significance of this advancement, stating: “Having access to this advanced, non-invasive blood test is a breakthrough for early Alzheimer’s diagnosis in the UK. Simplifying the diagnostic process means more patients can access crucial care sooner, especially as new treatments for early-stage Alzheimer’s continue to emerge.”
With LucentAD Complete, Advance Tests is paving the way for easier, faster, and more accurate Alzheimer’s diagnostics, providing hope to patients and healthcare providers alike.
